ECC 2015: New survival data from the Combi-v trial investigating a combination of two targeted therapies in melanoma

ECC 2015: New survival data from the Combi-v trial investigating a combination of two targeted therapies in melanoma

EMJ

4 years
556 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Updated results from the phase 3 COMBI-v trial of a combination of dabrafenib and trametinib for the first-line treatment of patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma showed that patients are living significantly longer on the combined therapy than patients treated with vemurafenib alone. The median overall survival time in patients with metastatic melanoma with V600 mutations in the BRAF gene who received the combination treatment was 25.6 months, whereas it was 18 months in patients receiving vemurafenib alone.

Presented at the European Cancer Conference (ECC) 2015 by Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France



European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Category: Prostate Cancer
1 Views
Cancer-News 2 days
The Impact of Therapy with External-Beam Radiotherapy
The Impact of Therapy with External-Beam Radiotherapy
Category: Prostate Cancer
1 Views
Cancer-News 2 days
Is there a correlation between the target volume of radiation?
Is there a correlation between the target volume of radiation?
Category: Prostate Cancer
0 Views
Cancer-News 2 days
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
Category: Pancreatic Cancer
0 Views
Cancer-News 2 days
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Category: Prostate Cancer
0 Views
Cancer-News 2 days
Servier's R&D Efforts in Oncology #ASH #ASH19
Servier's R&D Efforts in Oncology #ASH #ASH19
Category: News
1 Views
ash 2 days
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: News
0 Views
Cancer-News 4 days
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Category: Brain Cancer
5 Views
Cancer-News 5 days
Molecular AI Product: What's Next For Research?
Molecular AI Product: What's Next For Research?
Category: News
11 Views
Cancer-News 1 week
Molecular AI Product: Can It Be Used Now or Later?
Molecular AI Product: Can It Be Used Now or Later?
Category: News
9 Views
Cancer-News 1 week